Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
Key PointsNovo Nordisk could strengthen its obesity pipeline by buying out Kailera Therapeutics and Viking Therapeutics.
Novo Nordisk, a leading pharmaceutical company, faces challenges due to increasing competition in its diabetes and obesity drug markets. With new drugs expected to enter the field in the coming years, the company could be at risk of further decline. However, Novo Nordisk possesses a promising pipeline of drugs. To bolster this pipeline, the company may explore licensing deals or acquisitions.
Recently, Novo Nordisk acquired three obesity-related assets from Kallyope, a privately held biotech firm. If the company decides to pursue additional acquisitions, two potential targets are Kailera Therapeutics and Viking Therapeutics.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
